Thrombospondin-1 in Patients with Diabetic Nephropathy

Abdelwhab, Saeed; Fooda, Osman; Abdel-Maksoud, Sahar M.

doi:10.1007/s00596-010-0156-4

Cited by 4 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After release of thrombospondin from platelets, TSP-1 binds to the surface of activated platelets. In a previous report, levels of TSP-1 were suggested to confirm renal damage and vascular impairment in patients with diabetic nephropathy [ 208 ].…”

Section: Platelets Hyperactivity In T2dmmentioning

confidence: 99%

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Kaur

Singh

2018

Cardiovasc Diabetol

530

363

View full text Add to dashboard Cite

The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, accounting for approximately 90–95% of the total diabetes cases worldwide. Besides affecting the ability of body to use glucose, it is associated with micro-vascular and macro-vascular complications. Augmented atherosclerosis is documented to be the key factor leading to vascular complications in T2DM patients. The metabolic milieu of T2DM, including insulin resistance, hyperglycemia and release of excess free fatty acids, along with other metabolic abnormalities affects vascular wall by a series of events including endothelial dysfunction, platelet hyperactivity, oxidative stress and low-grade inflammation. Activation of these events further enhances vasoconstriction and promotes thrombus formation, ultimately resulting in the development of atherosclerosis. All these evidences are supported by the clinical trials reporting the importance of endothelial dysfunction and platelet hyperactivity in the pathogenesis of atherosclerotic vascular complications. In this review, an attempt has been made to comprehensively compile updated information available in context of endothelial and platelet dysfunction in T2DM.

show abstract

Section: Platelets Hyperactivity In T2dmmentioning

confidence: 99%

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Kaur

Singh

2018

Cardiovasc Diabetol

530

363

View full text Add to dashboard Cite

show abstract

“…Increased synthesis of TXA2 indicates that "resting" platelets of diabetics in general tend to be activated. TXA2 is a vasoconstrictor and prothrombotic factor with the risk of atherothrombogenesis present in DM [53] . Moreover, synthesis of TXB2 has inverse correlation with the minimal level of arachidonic acid inevitable to 50% platelet aggregation.…”

Section: Txb2mentioning

confidence: 99%

Endothelial and platelet markers in diabetes mellitus type 2

Kubisz¹,

Stančiaková²,

Staško³

et al. 2015

WJD

View full text Add to dashboard Cite

Diabetes mellitus (DM) is an extremely common disorder which carries a risk of vascular impairment. DM type 2 (DM2) can be characterized by the dysfunction of haemostasis manifesting by stimulated coagulation process, disorder of platelet function and decreased fibrinolytic activity. These all are the reasons why DM2 is the most common acquired thrombophilia. Endothelial dysfunction along with platelet hyperactivity are unquestionably involved in the hyperactivation of platelets and clotting factors in DM. As a natural consequence of continuous investigation, many markers of endothelial dysfunction and diabetic thrombocytopathy have been identified and considered for implementation in clinical practice. Endothelial function can be assessed by the evaluation of endothelial markers, circulating molecules synthesised in various amounts by the endothelium. These markers precede the signs of evident microangiopathy. Platelets have an ethiopathogenic relation to the microangiopathy in DM. Their increased activity was confirmed in both types of DM. Predictors of endothelial and platelet disorder could improve the screening of individuals at increased risk, thus leading to the early diagnosis, appropriate treatment, as well as to the effective prevention of the complications of DM2. In the article we deal with the mechanisms involved in the pathogenesis of endothelial and platelet functional abnormalities, endothelial and platelet markers of DM2 considered for implementation in clinical practice and possibilities of their detection.

show abstract

“…Thrombospondins are multifunctional glycoproteins that are involved in the regulation of angiogenesis, cell proliferation, cell adhesion and migration, modulating platelet aggregation, apoptosis, activation of protein kinase, and TGF-β activity [ 132 , 135 ]. As a typical matrixcellular protein, TSP-1 is tightly regulated by cytokines such as PDGF, FGF-2, or TGF-β, and by various possible interactions with other cytokines, receptors, and proteases [ 132 ].…”

Section: Role Of Platelet In Pathogenesis Of Dkdmentioning

confidence: 99%

“…A study of TSP-1 in patients with DKD also showed that serum TSP-1 is significantly higher in patients with DKD than in normal control subjects [ 132 , 135 ]. TSP-1 levels correlate with the degree of renal impairment and vascular disease in patients.…”

Section: Role Of Platelet In Pathogenesis Of Dkdmentioning

confidence: 99%

“…These aspects were related to the ability of TSP-1 to enhance latent TGF-β bioactivity, which is a profibrotic cytokine that mediates glomerular response to injury through glomerular hypertrophy, matrix expansion, and glomerulosclerosis. The functional activity of the TSP-1/TGF-β axis was shown to be involved in the tubulointerstitial injury of patients with DKD [ 135 ].…”

Section: Role Of Platelet In Pathogenesis Of Dkdmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Platelets in Diabetic Kidney Disease

Rustiasari

Roelofs

2022

IJMS

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is among the most common microvascular complications in patients with diabetes, and it currently accounts for the majority of end-stage kidney disease cases worldwide. The pathogenesis of DKD is complex and multifactorial, including systemic and intra-renal inflammatory and coagulation processes. Activated platelets play a pivotal role in inflammation, coagulation, and fibrosis. Mounting evidence shows that platelets play a role in the pathogenesis and progression of DKD. The potentially beneficial effects of antiplatelet agents in preventing progression of DKD has been studied in animal models and clinical trials. This review summarizes the current knowledge on the role of platelets in DKD, including the potential therapeutic effects of antiplatelet therapies.

show abstract

Thrombospondin-1 in Patients with Diabetic Nephropathy

Cited by 4 publications

References 29 publications

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Endothelial and platelet markers in diabetes mellitus type 2

The Role of Platelets in Diabetic Kidney Disease

Contact Info

Product

Resources

About